Title | Progranulin promotes melanoma progression by inhibiting natural killer cell recruitment to the tumor microenvironment. |
Publication Type | Journal Article |
Year of Publication | 2019 |
Authors | Voshtani R, Song M, Wang H, Li X, Zhang W, Tavallaie MS, Yan W, Sun J, Wei F, Ma X |
Journal | Cancer Lett |
Volume | 465 |
Pagination | 24-35 |
Date Published | 2019 Nov 28 |
ISSN | 1872-7980 |
Keywords | Animals, Cell Line, Tumor, Cell Proliferation, Chemokine CCL5, Disease Progression, Female, Gene Expression Regulation, Neoplastic, Humans, Killer Cells, Natural, Melanoma, Mice, Neoplasm Metastasis, Neoplasm Transplantation, Prognosis, Progranulins, Transcription, Genetic, Tumor Microenvironment, Up-Regulation |
Abstract | Progranulin (PGRN) is a growth factor with significant biological effects in different types of cancer. However, its role in melanoma progression has not been explored. In this study, we first analyze clinical datasets and show that high PGRN expression levels are correlated with poor prognosis of melanoma patients. Further, we demonstrate in a transplanted murine melanoma model in which the endogenous Grn gene encoding PGRN has been deleted that tumor-derived, not host-derived PGRN, promotes melanoma growth and metastasis. Immunological analyses reveal an enhanced infiltration of natural killer cells, but not T lymphocytes, into PGRN-deficient tumors compared to the wild type control. Antibody-mediated depletion confirms the critical role of NK cells in controlling B16 tumor growth. RNA-seq analysis reveals that several chemokines including CCL5 are strongly upregulated in PGRN-deficient tumor. Silencing CCL5 expression in PGRN-deficient tumor reduces NK cell recruitment and restores tumor growth to the control level. Lastly, we show that PGRN inhibits Ccl5 gene expression at the transcriptional level. This study highlights a novel and critical role of PGRN in melanoma growth and metastasis and suggests that it may represent a potential therapeutic target. |
DOI | 10.1016/j.canlet.2019.08.018 |
Alternate Journal | Cancer Lett |
PubMed ID | 31491449 |
PubMed Central ID | PMC7519469 |
Grant List | P30 CA008748 / CA / NCI NIH HHS / United States R56 AI095512 / AI / NIAID NIH HHS / United States R56 AI103157 / AI / NIAID NIH HHS / United States |
Submitted by wcm_microbiolog... on October 14, 2020 - 1:48pm